Fundraising FoxIkarian Capital — Full Portfolio
4 tracked investments · listed companies and verified rows first
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.
BiotechHealthtechRedwood City, US
Judith Shizuru(Director)Herb Cross(Executive Officer)inJeet Mahal(Executive Officer, Director)inPatrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)
Co-investorsAvego BioScience CapitalQiming Venture Partners USATSVCAbingworth
Jasper is a commercial real estate fund management firm that deploys and manages capital for institutional investors into industrial, logistics, and other asset classes across Australia and New Zealand.
Enterprise SoftwareFintechPropTechAuckland, NZ
Mark Campbell(CEO and Executive Director)in
Co-investorsBlackstoneArc AngelsFantail VenturesIcehouse VenturesBessemer Venture PartnersCoatue Management+5 more
Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases.
BiotechHealthtechCambridge, US
Wenru Song(Founder)in
Co-investorsForesite CapitalQuan CapitalVivo Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.